MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends MOR vs. PCVX, QGEN, ITCI, ROIV, ASND, RVMD, LNTH, NUVL, LEGN, and BPMCShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Vaxcyte (PCVX), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Legend Biotech (LEGN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Vaxcyte Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Legend Biotech Blueprint Medicines Vaxcyte (NASDAQ:PCVX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk. Do institutionals & insiders hold more shares of PCVX or MOR? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor PCVX or MOR? In the previous week, Vaxcyte had 11 more articles in the media than MorphoSys. MarketBeat recorded 13 mentions for Vaxcyte and 2 mentions for MorphoSys. Vaxcyte's average media sentiment score of 0.65 beat MorphoSys' score of -0.27 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is PCVX or MOR more profitable? Vaxcyte has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Vaxcyte's return on equity of -23.53% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% MorphoSys -226.79%-694.31%-22.55% Which has better earnings and valuation, PCVX or MOR? MorphoSys has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$4.60-18.81MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Which has more volatility and risk, PCVX or MOR? Vaxcyte has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Does the MarketBeat Community prefer PCVX or MOR? Vaxcyte received 20 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 75.00% of users gave Vaxcyte an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes4575.00% Underperform Votes1525.00% MorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Do analysts recommend PCVX or MOR? Vaxcyte presently has a consensus target price of $145.71, suggesting a potential upside of 68.40%. MorphoSys has a consensus target price of $14.33, suggesting a potential downside of 24.45%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00MorphoSys 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryVaxcyte beats MorphoSys on 12 of the 17 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$6.57B$5.13B$9.08BDividend YieldN/A2.99%4.91%4.22%P/E Ratio-5.4510.5591.4117.18Price / Sales11.99195.351,113.72116.79Price / CashN/A57.1642.7137.86Price / Book54.175.104.794.78Net Income-$205.35M$151.51M$120.07M$225.60M7 Day PerformanceN/A-2.14%-1.92%-1.23%1 Month PerformanceN/A-3.13%11.46%3.36%1 Year Performance109.50%11.53%30.49%16.59% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSys0.1298 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730News CoveragePCVXVaxcyte1.5995 of 5 stars$90.22+2.8%$147.50+63.5%+45.4%$11.25BN/A-19.07160Analyst ForecastInsider TradeQGENQiagen3.7415 of 5 stars$45.48+0.2%$51.15+12.5%+3.1%$10.38B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0406 of 5 stars$84.49+1.8%$97.23+15.1%+27.8%$8.96B$612.78M-95.91560ROIVRoivant Sciences3.0012 of 5 stars$12.08+2.0%$17.93+48.4%+16.2%$8.79B$129.13M2.10860Insider TradeASNDAscendis Pharma A/S3.1403 of 5 stars$137.20+5.6%$191.77+39.8%+12.6%$8.32B$327.43M-16.52640RVMDRevolution Medicines4.549 of 5 stars$44.77-0.5%$63.67+42.2%+71.5%$7.53B$11.58M-12.54443Insider TradeLNTHLantheus4.3768 of 5 stars$94.38+1.5%$130.00+37.7%+53.4%$6.56B$1.50B15.42834Analyst ForecastNUVLNuvalent2.1959 of 5 stars$86.65-0.2%$112.60+29.9%+16.9%$6.16BN/A-25.0340Insider TradeNews CoveragePositive NewsLEGNLegend Biotech1.553 of 5 stars$33.53-4.5%$81.54+143.2%-43.2%$6.12B$520.18M-36.971,800BPMCBlueprint Medicines2.5727 of 5 stars$95.23+2.2%$122.11+28.2%+7.2%$6.05B$434.42M-45.28640Insider Trade Related Companies and Tools Related Companies PCVX Competitors QGEN Competitors ITCI Competitors ROIV Competitors ASND Competitors RVMD Competitors LNTH Competitors NUVL Competitors LEGN Competitors BPMC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MOR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
